What's Happening?
Bracco Imaging has launched an Early Access Program for its BubbleGen technology, designed to streamline cell therapy manufacturing. The technology uses buoyant microbubbles for cell separation and activation, offering an alternative to traditional magnetic
bead-based methods. BubbleGen targets specific cell subtypes, including rare populations, and is showcased at the ISCT 2026 conference. The program allows researchers to evaluate the technology's performance and provide feedback for future development. Bracco aims to support cell therapy developers in optimizing processes and improving sample purity.
Why It's Important?
The introduction of BubbleGen technology represents a significant advancement in cell therapy manufacturing, potentially improving efficiency and flexibility in cell selection and activation. By offering an alternative to magnetic bead-based methods, BubbleGen could enhance the precision and effectiveness of cell therapies, particularly in targeting rare cell populations. The Early Access Program provides an opportunity for researchers to explore new workflows and contribute to the technology's refinement. This innovation aligns with the growing demand for advanced tools in the rapidly evolving field of cell and gene therapy.
What's Next?
Participants in the Early Access Program will evaluate BubbleGen's performance across various applications and provide feedback to guide its development. Bracco plans to work closely with researchers to optimize experimental designs and troubleshoot challenges. The company may expand the technology's capabilities and explore additional applications in cell therapy. The success of BubbleGen could lead to broader adoption in the industry and inspire further innovations in cell therapy manufacturing.
